iRhythm Technologies, Inc.
HealthcareNASDAQ:IRTC · NASDAQ Global Select
+$0.98 today
Vol 0.28M · Avg 0.53M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$787.9M of revenue converted into -$27.8M of net income for the selected period. Gross margin is 71.0% and net margin is -3.7%, showing how much revenue survives after costs and taxes. EPS is $-0.86, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $747.1M +26.2% | $591.8M +20.1% | $492.7M +19.9% | $410.9M +27.3% | $322.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $219.9M +19.3% | $184.3M +14.6% | $160.9M +24.4% | $129.3M +18.3% | $109.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $527.3M +29.4% | $407.5M +22.8% | $331.8M +17.8% | $281.6M +31.9% | $213.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 70.6% +1.7pp | 68.9% +1.5pp | 67.3% -1.2pp | 68.5% +2.4pp | 66.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $84.6M -18.5% | $103.8M +72.3% | $60.2M +29.3% | $46.6M +20.5% | $38.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $479.4M +14.5% | $418.6M +8.5% | $385.6M +19.7% | $322.2M +17.2% | $274.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $564.1M +7.8% | $523.0M +14.5% | $457.0M +15.6% | $395.4M +26.1% | $313.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $26.5M +2.7% | $25.8M +16.4% | $22.1M +12.9% | $19.6M +18.2% | $16.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$4.0M +94.7% | -$74.1M +23.5% | -$96.9M -5.1% | -$92.1M -10.7% | -$83.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -0.5% +12.0pp | -12.5% +7.1pp | -19.7% +2.8pp | -22.4% +3.4pp | -25.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$36.8M +68.1% | -$115.5M +7.7% | -$125.2M -10.0% | -$113.8M -13.8% | -$99.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -4.9% +14.6pp | -19.5% +5.9pp | -25.4% +2.3pp | -27.7% +3.3pp | -31.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $21.5M -1.9% | $21.9M +256.4% | $6.2M +161.9% | $2.4M +1891.5% | $118.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.2M +2.6% | $12.8M +251.3% | $3.6M -11.8% | $4.1M +254.0% | $1.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$6.8M -344.1% | $2.8M +11.0% | $2.5M +219.2% | -$2.1M -100.0% | -$1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$43.6M +61.3% | -$112.7M +8.1% | -$122.7M -5.8% | -$115.9M -14.7% | -$101.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -5.8% +13.2pp | -19.0% +5.8pp | -24.9% +3.3pp | -28.2% +3.1pp | -31.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $953.0K +68.7% | $565.0K -24.7% | $750.0K +178.8% | $269.0K -26.7% | $367.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$44.6M +60.7% | -$113.3M +8.2% | -$123.4M -6.2% | -$116.2M -14.6% | -$101.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -6.0% +13.2pp | -19.1% +5.9pp | -25.0% +3.2pp | -28.3% +3.1pp | -31.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +61.7% | -$4 +10.1% | -$4 -4.1% | -$4 -12.1% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +61.7% | -$4 +10.1% | -$4 -4.1% | -$4 -12.1% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $32.0M +2.6% | $31.2M +2.2% | $30.5M +2.0% | $29.9M +2.0% | $29.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $32.0M +2.6% | $31.2M +2.2% | $30.5M +2.0% | $29.9M +2.0% | $29.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Bruker Corporation
NASDAQ:BRKR
$8.26B
Glaukos Corporation
NYSE:GKOS
$7.45B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Teleflex Incorporated
NYSE:TFX
$5.78B
Chemed Corporation
NYSE:CHE
$5.57B
Bausch + Lomb Corporation
NYSE:BLCO
$5.38B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
RadNet, Inc.
NASDAQ:RDNT
$4.46B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IRTC generate?
iRhythm Technologies, Inc. (IRTC) reported $747.14M of revenue in fiscal 2025.
Is IRTC profitable?
iRhythm Technologies, Inc. (IRTC) reported -$44,551,000.00 of net income, with a net margin of -6.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.